Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexa's pyrolytic thumb implant:

This article was originally published in Clinica

Executive Summary

Nexa Orthopedics has received US FDA 510(k) clearance to sell its pyrolytic carbon carpometacarpal implant (CMI) for relieving basal thumb joint pain associated with arthritis, while improving the thumb's range of motion and biomechanical function. The San Diego, California firm added the product to its portfolio following its recent acquisition of BioProfile, which according to Nexa, has been marketing products in Europe for "many years". Nexa claims to be the only company in the world that designs, manufactures and distributes orthopaedic implants made of pyrolytic carbon. The CMI's official US launch is scheduled to take place in September 2006 at the American Society for Surgery of the Hand meeting, in Washington, DC.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel